Sapphiros will use the funding to develop its molecular diagnostic platform for biothreat and emerging infectious disease detection in point-of-care settings.

The Alzheimer's Drug Discovery Foundation (ADDF) said on Monday that it has partnered with the Michael J. Fox Foundation (MJFF) to develop minimally invasive biomarkers for Parkinson's and Alzheimer's ...

Last week, readers were most interested in a story about Roche's blood-based IGRA test for latent TB getting CE marking.

The updated test showed 80 percent sensitivity for detecting colorectal cancer overall and 18 percent sensitivity for advanced precancerous lesions.

Under the policy, blood-based tests may be eligible for coverage if they either are cleared or approved by the US FDA or measure phosphorylated-tau 217.

The firm began its early-access program in breast cancer in March and is now expanding the test's indications to include colorectal and renal cancers.

The firm said its long-term roadmap for the test includes addition of integrated, proprietary front-end automation in the future.

The platform, including the assay, specimen collection kit, and associated software, underwent a comprehensive review including evidence of analytical and clinical validity.